Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03937700 · ClinicalTrials.gov registry record · NA

Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker

A NA study of Cerebral Palsy, sponsored by Shirley Ryan AbilityLab.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03937700: Active NA study of Cerebral Palsy, sponsored by Shirley Ryan AbilityLab.

NCT03937700 is a NA study of Cerebral Palsy that is active but no longer recruiting, run by Shirley Ryan AbilityLab. The registered enrollment target is 30 participants, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03937700, a NA study of Cerebral Palsy, is active but no longer recruiting, sponsored by Shirley Ryan AbilityLab.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy

Primary Outcome

This test will examine the patient's gait speed. Patients will be directed to walk at their preferred and maximum but safe speed. Patients will be positioned 1 meter before the start line and instructed to walk the entire 10-meter distance and past the end line approximately 1 meter. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be recorded using a stopwatch and recorded to the one hundredth of a second.

Conditions Studied

Interventions

  • DEVICE CPWalker Robotic Exoskeleton

Study Locations (1)

Illinois

  • Shirley Ryan AbilityLab - Chicago

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-07-01
Est. Completion 2025-12-01
Phase NA
Shirley Ryan AbilityLab

138 total trials

What the registry record for NCT03937700 still lists

NCT03937700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Cerebral Palsy appearing as the primary indexed condition, and to 1 intervention - of which CPWalker Robotic Exoskeleton is the first listed.

NCT03937700 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT03937700 about?

NCT03937700 is a clinical study titled "Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker". This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy

What is the current status of trial NCT03937700?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-07-01. Estimated completion is 2025-12-01.

What conditions does trial NCT03937700 study?

This clinical trial studies the following conditions: Cerebral Palsy.

What interventions are being tested in trial NCT03937700?

The interventions under investigation include: CPWalker Robotic Exoskeleton (DEVICE).

Who is sponsoring clinical trial NCT03937700?

This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03937700 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03937700's enrollment target sits among peer trials

30 55th of 91 higher than 29 of 91 other Cerebral Palsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cerebral Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03937700, the US trial registry maintained by the National Library of Medicine. NCT03937700 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.